<DOC>
	<DOC>NCT02242760</DOC>
	<brief_summary>This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.</brief_summary>
	<brief_title>P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Moderate to severe acne 2570 noninflammatory lesions at Baseline 2040 inflammatory lesions at Baseline Subjects with known allergy to any component of the test material or vehicle Women who are pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>acne</keyword>
</DOC>